Arcus Biosciences to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
27 Julho 2022 - 5:01PM
Business Wire
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global
biopharmaceutical company focused on developing differentiated
molecules and combination therapies for people with cancer,
announced that its management team will participate in a virtual
fireside chat at the upcoming 13th Annual Wedbush PacGrow
Healthcare Conference. The fireside chat will take place on
Wednesday, August 10th, 2022 at 12:00 p.m. ET.
A live webcast of the fireside chat will be available by
visiting the “Investors & Media” section of the Arcus
Biosciences website at www.arcusbio.com. A replay of the webcast
will be available following the live event.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage, global biopharmaceutical
company developing differentiated molecules and combination
medicines for people with cancer. In partnership with industry
partners, patients and physicians around the world, Arcus is
expediting the development of first- or best-in-class medicines
against well characterized biological targets and pathways and
studying novel, biology-driven combinations that have the potential
to help people with cancer live longer. Founded in 2015, the
company has expedited the development of six investigational
medicines into clinical studies, including new combination
approaches that target TIGIT, PD-1, the adenosine axis (CD73 and
dual A2a/A2b receptor) and most recently, HIF-2a. For more
information about Arcus Biosciences’ clinical and pre-clinical
programs, please visit www.arcusbio.com or follow us on
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220727005061/en/
Media Inquiries Holli Kolkey VP of Corporate
Communications (650) 922-1269 hkolkey@arcusbio.com
Investor Inquiries Pia Banerjee Head of Investor
Relations & Strategy (617) 459-2006 pbanerjee@arcusbio.com
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Arcus Biosciences (NYSE:RCUS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024